EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Health Economic Evaluation of Lung Cancer Screening Using a Diagnostic Blood Test: The Early Detection of Cancer of the Lung Scotland (ECLS)

Jose Antonio Robles-Zurita, Nicola McMeekin, Frank Sullivan iD, Frances S Mair iD, Andrew Briggs

Current Oncology · 2024

DOI: 10.3390/curroncol31060261 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Oncology, 2024. Verfasst von Jose Antonio Robles-Zurita und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Applied Economics (Statistics and Econometrics), University of Malaga, El Ejido nº 6, 29013 Malaga, Spain. Hauptthemen laut MEDLINE: Lung Neoplasms, Early Detection of Cancer, Cost-Benefit Analysis. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Scottish Government Health and Social Care Directorates, Oncimmune Ltd, Oncimmune Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Diagnostic blood tests have the potential to identify lung cancer in people at high risk. We assessed the cost-effectiveness of a lung cancer screening intervention, using the EarlyCDT®-Lung Test (ECLS) with subsequent X-ray and low-dose chest CT scans (LDCT) for patients with a positive test result, compared to both usual care and LDCT screening for the target population.

Methods

We conducted a model-based lifetime analysis from a UK NHS and personal social services perspective. We estimated incremental net monetary benefit (NMB) for the ECLS intervention compared to no screening and to LDCT screening.

Results

The incremental NMB of ECLS intervention compared to no screening was GBP 33,179 (95% CI: −GBP 81,396, GBP 147,180) and GBP 140,609 (95% CI: −GBP 36,255, GBP 316,612), respectively, for a cost-effectiveness threshold of GBP 20,000 and GBP 30,000 per quality-adjusted life year. The same figures compared with LDCT screening were GBP 162,095 (95% CI: GBP 52,698, GBP 271,735) and GBP 52,185 (95% CI: −GBP 115,152, GBP 219,711).

Conclusions

The ECLS intervention is the most cost-effective screening alternative, with the highest probability of being cost-effective, when compared to no screening or LDCT screening. This result may change with modifications of the parameters, suggesting that the three alternatives considered in the main analysis are potentially cost-effective.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsEarly Detection of CancerCost-Benefit AnalysisHumansScotlandFemaleMaleMiddle AgedTomography, X-Ray ComputedAgedHematologic TestsMass Screening

Stichwörter der Autor:innen

cost-effectivenessdiagnostic blood testeconomic evaluationlung cancerscreening

Autor:innen und Institutionen

  • Department of Applied Economics (Statistics and Econometrics), University of Malaga, El Ejido nº 6, 29013 Malaga, Spain.
  • Health Economics and Health Technology Assessment (HEHTA), School of Health and Wellbeing, University of Glasgow, Glasgow G12 8TP, UK.
  • School of Medicine, University of St Andrews, St Andrews KY16 9AJ, UK.
  • Department of Family and Community Medicine, University of Toronto, Toronto, ON M5G 1V7, Canada.
  • General Practice and Primary Care, School of Health and Wellbeing, University of Glasgow, Glasgow G12 8TP, UK.
  • Faculty of Public Health and Policy, Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK.

ORCID-Profile: Frank Sullivan, Frances S Mair

Förderung

  • Scottish Government Health and Social Care Directorates
  • Oncimmune Ltd
  • Oncimmune Ltd.
  • Scottish Government Health & Social Care Directorate of the Chief Scientist Office (CSO)

Zitieren

APA

Robles-Zurita, J. A., McMeekin, N., Sullivan, F., Mair, F. S., & Briggs, A. (2024). Health Economic Evaluation of Lung Cancer Screening Using a Diagnostic Blood Test: The Early Detection of Cancer of the Lung Scotland (ECLS). Current Oncology. https://doi.org/10.3390/curroncol31060261

Vancouver

Robles-Zurita JA, McMeekin N, Sullivan F, Mair FS, Briggs A. Health Economic Evaluation of Lung Cancer Screening Using a Diagnostic Blood Test: The Early Detection of Cancer of the Lung Scotland (ECLS). Current Oncology. 2024. doi:10.3390/curroncol31060261

BibTeX
@article{RoblesZurita2024,
  author = {Robles-Zurita, Jose Antonio and McMeekin, Nicola and Sullivan, Frank and Mair, Frances S and Briggs, Andrew},
  title = {Health Economic Evaluation of Lung Cancer Screening Using a Diagnostic Blood Test: The Early Detection of Cancer of the Lung Scotland (ECLS)},
  journal = {Current Oncology},
  year = {2024},
  doi = {10.3390/curroncol31060261}
}
Kostenlos starten →